Literature DB >> 16220763

Preoperative serum CA-125 levels in treating endometrial cancer.

John L Powell1, Kelly A Hill, Brian C Shiro, Sandra J Diehl, Walter H Gajewski.   

Abstract

OBJECTIVE: To evaluate preoperative levels of CA-125 for the prediction of advanced stages of uterine cancer. STUDY
DESIGN: Retrospective chart review of 141 women with endometrial cancer who were treated by a single gynecologic oncologist at a community teaching hospital in North Carolina between November 1994 and September 2002.
RESULTS: Ninety-three of 106 patients (87.7%) with surgical stage I or II endometrial cancer had normal preoperative CA-125 levels. Ten of 11 (91%) women with stage IV endometrial cancer had elevated preoperative CA-125 levels. High CA-125 levels and positive lymph vascular space invasion correlated most strongly with advanced stage (p < 0.01). Similar trends in correlation of CA-125 levels were seen with the highest grade and the deepest myometrial invasion. The sensitivity and specificity of a CA-125 cutoff level of 35 U/mL were 63% and 88%, respectively, with a positive predictive value of 61% and negative predictive value of 89%.
CONCLUSION: Measurement of preoperative CA-125 is a clinically useful test in endometrial cancer patients. CA-125 appears to be a significant independent predictor of the extrauterine spread of disease and is a better predictor of disease than depth of invasion or grade. This evidence complements a growing body of literature that supports the strong relationship between CA-125 level and stage of disease. A CA-125 level should be included as part of the preoperative workup for all patients with endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220763

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  23 in total

1.  Current status in the management of uterine corpus cancer in Korea.

Authors:  Nan-Hee Jeong; Jong-Min Lee; Seon-Kyung Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

3.  The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer.

Authors:  Marina Frimer; June Y Hou; Thomas C McAndrew; Gary L Goldberg; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2012-09-20       Impact factor: 3.060

4.  Association of preoperative serum HE4 levels on the survival of patients with endometrial cancer.

Authors:  Putsarat Insin; Yani Yimyam; Nisa Prueksaritanond
Journal:  Arch Gynecol Obstet       Date:  2021-06-09       Impact factor: 2.344

5.  Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Authors:  Richard G Moore; Amy K Brown; M Craig Miller; Donna Badgwell; Zhen Lu; W Jeffrey Allard; C O Granai; Robert C Bast; Karen Lu
Journal:  Gynecol Oncol       Date:  2008-05-21       Impact factor: 5.482

Review 6.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

7.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

8.  Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study.

Authors:  Rupali Dewan; Abhinav Dewan; Swati Hare; Mausumi Bhardwaj; Krati Mehrotra
Journal:  J Clin Diagn Res       Date:  2017-07-01

9.  Serum amyloid A: a novel biomarker for endometrial cancer.

Authors:  Emiliano Cocco; Stefania Bellone; Karim El-Sahwi; Marilisa Cargnelutti; Natalia Buza; Fattaneh A Tavassoli; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

10.  The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.

Authors:  Beyhan Omer; Sema Genc; Ozguc Takmaz; Ahmet Dirican; Zeynep Kusku-Kiraz; Sinan Berkman; Figen Gurdol
Journal:  Tumour Biol       Date:  2013-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.